John Prista Freshley Email & Phone Number

Ann Arbor, MI, US

Ann Arbor, Michigan, US

Bioscience Navigators is dedicated to providing hands-on experienced business leadership for breakthrough science from universities and start-ups in often overlooked regions that will create attractive investor returns, the next-generation of bioscience leadership talent, and vibrant and sustainable bioscience ecosystems.With public benefit as a core.

Akeila Bio is developing next generation RXR drugs to treat a wide range of disease with major unmet patient needs. Akeila's RXR agonists combine the potency of prior RXR drugs, such as bexarotene, but without the dose-limiting toxicities of hypertriglyceridemia and hypercholesterolemia.

Ann Arbor, MI, US

Curio Genomics is developing powerful new ways to bring genomics insights to crop researchers and seed companies to meet the simultaneous challenges of malnutrition, population growth, and climate change.

Ann Arbor, Michigan, US

Support Cantilever Investors in identifying and evaluating life science investment opportunities, while also providing direct management expertise to portfolio companies.

Working with leading research institutes, including the Gulbenkian Institute of Science and NOVA University, in the A5 Corridor from Lisbon-to-Oeiras-to-Cascais focused on to creating value and innovating in the Health and Life Sciences. With leadership support from Nova University and the municipality of Oeiras, Venture A5 will leverage the institutes.

With my colleagues at Orange Grove Bio, I am excited to help launch another exciting University of Michigan biotech start-up. Asalyxa is developing its neutrophil-targeting delivery platform and lead candidate ASX-100 for ARDS and other critical inflammatory disorders.

Cincinnati, Ohio, US

Ann Arbor, Michigan, US

ONL Therapeutics (ONL) is a biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal diseases and conditions.By advancing a novel breakthrough technology designed to protect photoreceptors against programmed cell death (apoptosis), ONL is pioneering an entirely new approach to preserving sight. It is.

Ann Arbor, Michigan, US

Work with professors and staff at the University of Michigan to evaluate technology and the potential to launch start-up businesses. Leveraging a career in early phase start-up organizations, I assist faculty and staff in developing business models and plans, securing start-up funding, and building management teams.

Waltham, MA, US

As interim CEO in 2006-2007, I recruited Compendia's management team, led the development of Compendia's company culture, and secured the company's first 10 customers.I also led the company's efforts to secure early funding including $1.2M from Michigan's 21st Century Job Fund and a $2.4M Phase I-II Fast Track SBIR grant from the NIH.With funding secured.

Partnered with industry-leading scientists and lead fundraising and partnering activities focused on the in-licensing and development of cancer drugs utilizing personalized medicine approaches.

Led innovative drug development company focused on utilizing proprietary in-silico analysis to effectively develop cancer drugs with personalized medicine approach.

Wimbledon, London, GB

Led sales, marketing and corporate partnering activities.

B.A., Communications

Journalism

Education record

Education record